Lantern Pharma Inc. Share Price & Technical Analysis
LTRN · $3.50 (+5.42%)
Healthcare / Biotechnology
$3.50
+5.42%
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, …
Price chart
Seasonality
May has 3 positive and 1 negative years (last 5 years shown)
67% return in May, 2% avg return in past 3 year May month.
47% return in 2026, 4% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 7% | -10% | -50% | 33% | 67% | – | – | – | – | – | – | – | 47% |
| 25 | 53% | -18% | -8% | 0% | -17% | 3% | 42% | -5% | 5% | -9% | -10% | -17% | 20% |
| 24 | 0% | 12% | 83% | -43% | 15% | -23% | -12% | -2% | -12% | -18% | 3% | -3% | -1% |
| 23 | -2% | -10% | -11% | 2% | 6% | 8% | -18% | -4% | -26% | -26% | 67% | 8% | -7% |
| 22 | -15% | -9% | 16% | -17% | 0% | 0% | -9% | 2% | -8% | -12% | 16% | 22% | -13% |
Monthly return % by calendar month · historical pattern, not a forecast
Neutral · Emerging · Strong
Lantern Pharma Inc. focuses on the discovery and development of oncology drug in India. Its product pipeline comprises LP-300, which is in phase 2 clinical trial in combination therapy for never-smokers with non-small cell lung cancer adenocarcinoma; LP-184, which is in phase 1a clinical trial for the treatment of advanced or metastatic solid tumors, or unresectable or recurrent GBM, solid tumor, such as pancreatic, breast, bladder, and lung cancers, as well as glioblastoma and other central nervous system (CNS) cancers; and LP-284, which is in phase 1 clinical trial for the treatment of non-Hodgkin's lymphomas, including mantle cell lymphoma and double hit lymphoma. The company also develops STAR-001, which is in preclinical development for the treatment of glioblastoma, brain metastases, atypical teratoid rhabdoid tumors, and several rare pediatric CNS cancers. In addition, it provides ADC program, an antibody drug conjugate therapeutic approach for cancer treatment. The company has a strategic AI-driven collaboration with Oregon Therapeutics to optimize the development of its first-in-class protein disulfide isomerase inhibitor drug candidate XCE853 in novel and targeted cancer indications; a collaboration agreement with TTC Oncology, which focuses on the drug development of TTC-352 to treat patients with metastatic ER+ breast cancer; and a collaboration agreement with Actuate Therapeutics, Inc. that focuses on the development of compounds for use in the treatment of cancer and inflammatory diseases leading to fibrosis. The company was incorporated in 2013 and is headquartered in Dallas, Texas.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$22.95M
P/E ratio
—
52W high
$5.74
52W low
$1.11
Volume
4,50,890
Beta
2.10
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Lantern Pharma Inc. share price today?
- Lantern Pharma Inc. (LTRN) last traded around $3.50 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does LTRN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for LTRN. Download the app for real-time alerts.
- How can I analyze Lantern Pharma Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.